Tagged with Teva,

Czech Republic A current lack of transparency in Czech healthcare spending is severely detrimental to all industry stakeholders. However, new synergies between the private and public sectors are helping to clear these murky waters.   The Czech Republic, with a population of about 10.5 million, is the third most populous country within Central…

Pharma Teva Czech Republic & Slovakia GM Juan Carlos Conde describes how the Czech Republic hosts Teva’s third largest manufacturing site within Europe and the recent implementation of a more efficient cluster organization covering the Czech and Slovakian markets. You became general manager of Teva Pharmaceuticals Czech Republic & Slovakia eight…

Pharma Teva Benelux and Nordics’ GM lifts the lid on how the company has grown to become the market leader in the Netherlands. Looking at Teva’s activities, your market leader position in the Netherlands and your global ambitions, a truly ambitious culture emanates from TEVA’s achievements. Where does this drive come from?…

Generics The president & CEO of Canada’s largest generics player considers the current market dynamics for generic products, including IP regulation, generic penetration, and the advantages of balancing branded and non-branded products.  What was the strategy behind the integration of Novopharm into Teva? Novopharm is one of the pioneers in the…